Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
insomnia
Biotech
J&J's oral add-on aces phase 3 in major depressive disorder
J&J's oral drug improved depressive symptoms and sleep in a phase 3 trial for patients who previously did not benefit from antidepressants alone.
Gabrielle Masson
May 29, 2024 11:55am
FDA clears Neurovalens' neurostim headset for chronic insomnia
Nov 6, 2023 10:19am
Idorsia lays off 300 staff after previewing cost cuts in July
Oct 24, 2023 10:30am
ResMed continues German expansion with Mementor buy
Aug 2, 2022 1:00pm
Pear Therapeutics predicts ripening revenue after SPAC pact
Mar 29, 2022 12:31pm
SoftBank to bring Pear’s digital insomnia therapeutics to Japan
Mar 21, 2022 10:17am
